Medical/Pharmaceuticals
Acer Expands SpatialLabs Pro Ecosystem with Immersive 3D Capabilities Across Multiple Verticals
Editor's Summary * Integration with NVIDIA Omniverse libraries via OpenXR runtime supports enhanced spatial awareness for industrial designs and simulations * Partnership with Video Engineering brings 3D stereo microscopy to inspection, design, and prototyping workflows * Collaboration with...
2025-09-03 17:40
1680
Acer Medical Unveils aiMed Ahead of IFA 2025, Showcasing the Future of AI in Healthcare
BERLIN, Sept. 3, 2025 /PRNewswire/ -- Acer Medical, an Acer Group company specializing in medical imaging and AI-powered healthcare solutions, unveiled aiMed, its next-generation generative AI medical documentation system at the next@acer global press conference, ahead ofIFA 2025 in Berlin. The mi...
2025-09-03 17:30
1995
DeepQure Strengthens Clinical Leadership with Former SoniVie Executive Appointment
SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- DeepQure, a company pioneering a paradigm shift in hypertension treatment, today announced the appointment ofJason G. Jones as Global Vice President of Clinical & Regulatory Affairs. Jason joins DeepQure from SoniVie, an Israeli company developin...
2025-09-03 10:52
1764
Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer's disease and Dementia Data
* Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data * Enhancing dementia research by integrating AI imaging solutions with real-world data platforms SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Neurophet...
2025-09-02 21:00
2716
Lunit Selected as Exclusive AI Partner for Spain's Valencian Community Breast Screening Program
Milestone European deployment underscores growing global trust in Lunit's AI for population-wide breast cancer screening SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its solutions h...
2025-09-02 21:00
2101
Desilo to Launch "HARVEST™," Encrypted Data Collaboration Platform for Healthcare, in December
SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Desilo Inc., a privacy-technology startup specializing in cryptographic data collaboration, announced plans to launch its new healthcare platform,HARVEST™, this December. The platform is designed to allow medical institutions and pharmaceutical c...
2025-09-02 21:00
1957
BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform
XI'AN, China, Sept. 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds f...
2025-09-02 20:30
3868
SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift
* Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 * Rising demand for 2-dose regimen as international standards amid projected global market growth toUSD 6.3 billion by 3034 * SKBS continues strategic R&D to enhance global vaccine comp...
2025-09-02 19:00
2337
Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
- Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion - On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the fourth quarter of 2025 HONG KONG, Sept. 2, 2025 /PRNe...
2025-09-02 18:00
1484
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine...
2025-09-02 17:52
1586
Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy
HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination the...
2025-09-02 16:00
1462
AMI Pharm's AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in Nonsurgical Fat Reduction
* AMI Pharm's 'AYP-101' Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success * 'AYP-101,' a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics * 'AYP-101' Demonstrates Superior Safety and Efficacy, Poised to Change the ...
2025-09-01 21:00
1525
Jenscare, releases 2025H1 interim results
BEIJING, Sept. 1, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with TTVR breakthroughs, achieved milestones in its product portfolio globally, and just released its interim results for 2025H1 endedJune 30, 2025...
2025-09-01 13:00
5172
Jacobio Pharma Announces 2025 Interim Results
BEIJING and SHANGHAI and BOSTON, Aug. 29, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced its interim results for the six months endedJune 30, 2025. During the reporting period, the Company achieved revenue of RMB45.7 million, representing a 100% increase compared with the same per...
2025-08-30 00:25
5639
United Imaging Healthcare Reports 2025H1 Financial Results: Achieves Record Revenue in Overseas market
SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first half of 2025, maintaining steady growth. The company's revenue and net profit attributable to ...
2025-08-29 20:00
2401
YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market
* Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market Expansion * Trading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market onAugust 29, 2025, under the ticker symbols "YDES" and "YDESW" NEW YO...
2025-08-29 19:30
2883
Taiwan's Smart Healthcare Pavilion Presents Precision Oncology and Telemedicine Applications at Taiwan Expo USA 2025
DALLAS, Aug. 29, 2025 /PRNewswire/ -- At Taiwan Expo USA 2025 in Dallas, the Smart Healthcare Pavilion, organized by the International Trade Administration (TITA) and the Taiwan External Trade Development Council (TAITRA), highlighted Taiwan's accelerating role in global digital health innovation....
2025-08-29 17:32
1925
Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs
TOKYO, Aug. 28, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid's proprietary platform of hema...
2025-08-28 22:00
1293
D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers
* Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior treatment with platinum-based chemotherapy and anti-PD-(L)1 antibody but have not been previously treate...
2025-08-28 21:00
3521
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...
2025-08-28 20:00
3233
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 326 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 301 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09